Objective: Mephedrone is a stimulant drug chemically related to amphetamine, with effects similar to those of amphetamine and cocaine. This study aims to analyse fatalities following ingestion of mephedrone in the UK amongst 16-24 year olds in 2009-13, providing an update on data presented at the 2nd International Conference on Novel Psychoactive Substances.
INTRODUCTION
Mephedrone is a synthetic drug related to the naturally occurring stimulant cathinone found in the leaves of the khat plant (Catha edulis) which have been chewed and enjoyed socially for centuries in Africa for their stimulant properties (Kalix, 1990; Kalix, 1992) . Mephedrone is one of the several novel psychoactive substances (NPS; commonly known in the market by several terms such as: "designer drugs", "herbal highs", "legal highs", "laboratory reagents", and "research chemicals"), belonging to the class of synthetic cathinones Warnings that the contents are not for human consumption are added to packaging in an attempt to escape legal and civil sanctions.
Pharmacology
The pharmacology of mephedrone is characterised by monoamine reuptake inhibition involving the dopamine, norepinephrine and serotonin transporters thus accounting for their cocaine-and amphetamine-like effects (Meltzer et al., 2006; Dargan et al., 2011) . The dopamine (DAT) norepinephrine (NET) and serotonin transporters (SERT) strongly regulate the amount of neurotransmitters released into the synaptic cleft, influencing the extent and duration of neuronal signals. Mephedrone also increases presynaptic release of the same monoamines through changes in vesicular pH and inhibition of the vesicular monoamine transport receptor (VMAT2) which is located on the vesicular membrane and responsible for monoamine uptake into the vesicles for storage (Cozzi et al., 1999) . In addition, mephedrone exhibits relevant (<10 mM) 5-HT2A receptor binding (López-Arnau et al., 2012) and binds to α1-adrenergic receptors (Simmler et al., 2013) .
Routes of administration and dosages
Mephedrone is most commonly used by nasal insufflation/snorting of powder; or oral ingestion of powder dissolved in liquid, or 'bombing' (wrapped in paper), or in capsule or tablet form (James et al., 2011; Carhart-Harris et al., 2011) . Rectal administration, inhalation, and intramuscular or intravenous injection have also been described (Psychonaut Web Mapping Research Group, 2009; Newcombe, 2009) (Wood et al., 2010) ; intravenous doses are one half or two-thirds of the oral dose; rectal about 100 mg (Psychonaut Web Mapping Research Group, 2009) .
Typical users and effects
Mephedrone use became popular in the UK during 2009 among a wide population of older adolescents and young adults due, in part, to its desired psychoactive effects, cheapness, legal status, and easy availability online (Psychonaut Web Mapping Research Project, 2010) .
Young people can easily search the Internet without parental control (Tsitsika et al., 2009) and find many sites that emphasise the positive effects of this drug and minimise its negative Typical UK mephedrone consumers are young adults, mainly males, with a history of stimulant and polydrug use (Carhart-Harris et al., 2011) . This profile is similar to that of consumers of typical amphetamine-type stimulants (including amphetamine, methylamphetamine, ecstasy, and ecstasy-type drugs) (De Letter et al. 2006) . Over 40% of UK dance club drug users have reported the use of mephedrone (Winstock et al., 2011) , and it is commonly used by patrons of UK and European nightclubs (Wood et al., 2012; Yamamoto et al., 2013) . Mephedrone use has continued in the UK despite its prohibition.
The 2012/13 sweep of the Crime Survey for England and Wales (Home Office, 2013) found that use of mephedrone among young adults aged 16 to 24 years fell from 3.3% in 2011/12 to 1.6% in 2012/13. A self-selected sample of respondents reported a fall in use of the drug from 19.5% to 13.8%, in part due to its unwanted effects on mental health (Winstock, 2013) .
Users report mephedrone's effects as somewhere between amphetamine, cocaine and ecstasy (Measham et al., 2010) mephedrone may be associated with a number of both physical and psychopathological side effects especially reported in persons with psychiatric, cardiac or neurological issues, who may have a higher risk of side-effects . The most common adverse effects reported in mephedrone users who require medical care include: gastrointestinal symptoms (loss of appetite, dry mouth, nausea, vomiting) neurological signs (tremors, tense jaws, bruxism, headache, dizziness, seizures) and cardiovascular effects (tachycardia, elevated blood pressure, respiratory difficulties, chest pain, peripheral vasoconstriction; (Schifano et al., 2011) , and psychiatric symptoms (anxiety, aggression, agitation, confusion, dysphoria, depression, irritability; time distortions, long-lasting hallucinations, paranoid delusions, shortterm psychosis, short-term mania; insomnia and nightmares; impaired short-term and working memory). Several studies have also shown that cardiovascular and central nervous system (CNS) effects of mephedrone are related to its stimulation of the catecholaminergic system, which can lead to severe acute intoxication and high risk of fatal consequences (Meltzer et al., 2006; Durham, 2011) . Withdrawal effects following mephedrone use most frequently include tiredness, insomnia, nasal congestion and impaired concentration (Winstock et al., 2011) .
Emergency department admissions and fatalities
Although many individuals have presented at Emergency Departments (EDs) following exposure incidents and acute toxicity due to the ingestion of mephedrone, Wood et al. (2013) suggest that controlling mephedrone reduced the number of UK ED presentations with acute toxicity. Mephedrone is often used with other psychostimulants such as cocaine, amphetamine, benzylpiperazine, butylone, methylone or pentylone; such use is thought to enhance their stimulant and entactogen effects (Schifano et al., 2011) . Mephedrone is sometimes used in association with alcohol or controlled substances including heroin (EMCDDA, 2010), cocaine, cannabis, ketamine (ACMD, 2010) . Such drug combinations can result in fatal intoxication, as the co-occurrence of several stimulants might enhance both dopaminergic and serotonergic stimulation, increasing the potential for serotonin syndrome and fatal intoxication to occur (Schifano et al., 2004) . Most amphetamine, methylamphetamine and ecstasy victims die of polydrug ingestion .
Mephedrone-fatalities among young people have been described in several studies. The earliest case report was in 2008 of an 18-year-old Swedish woman, where mephedrone was the only substance detected post mortem (Morris, 2010) . A 22 year old US male died of accidental multiple drug toxicity; mephedrone along with morphine, codeine, and doxylamine, was detected in post-mortem samples (Dickson et al., 2010) . Two UK cases of two teenagers aged 18 and 19 years old who died after taking mephedrone were noted by Dyer (2010) . The death of a 19-year-old male who died of cardio-respiratory arrest after consuming an unknown quantity of mephedrone along with alcohol and "ecstasy" was reported together with a fatal intoxication of a 17 year old male where toxicological analysis disclosed mephedrone have been reported (Maskell et al., 2011) . Cosbey et al. (2013) reported 32 mephedrone-related poisonings, including fatalities, predominantly among young adult males, in Northern Ireland; only two were attributed directly to mephedrone toxicity.
The National Programme on Substance Abuse Deaths (NPSAD) has previously reported on 60 UK mephedrone-fatalities in the UK, ages ranged from 14 to 64 years. Overall (n = 36 where quantified) post mortem blood levels were mean = 1.59 mg/L, range = <0.01 -22.0 mg/L, excluding one outlier with a level of >2000 mg/L (Schifano et al., 2012; Corkery et al., 2012a) . Cosbey et al. (2013) noted that in fatal cases in which death was attributed directly to mephedrone toxicity alone, blood mephedrone concentrations were approximately 2.0 mg/L. This concentration is similar to the single case reported by Maskell et al. (2011) , in which mephedrone was considered to be the primary cause of death (blood mephedrone concentration of 2.24 mg/L) (Maskell et al. 2011) . Moreover, Torrance et al. (2010) found that post-mortem blood concentrations detected in confirmed mephedrone-related deaths were between 0.13 and 22 mg/L.
METHODS
A literature review using the PubMed, PsycINFO, Embase and Medline databases was undertaken, focusing on mephedrone's effects, pharmacology, toxicity, fatalities and public health harms related to its use in people aged 16-24 years. This age group was chosen because of its use in UK prevalence surveys and other indicators.
Fatalities involving mephedrone were then extracted from the NPSAD database. The Programme has been collecting and analysing drug-related deaths in the UK since 1997 with Coroners and relevant regional authorities submitting information voluntarily on drug-related deaths (Corkery et al., 2014) . To date, details of some 30,000 deaths have been received.
For a case to qualify as a 'mephedrone-related death' for the purposes of this paper, it had to fulfil one or more of the following criteria: 'mephedrone' or '4-methylmethcathinone' either implicated in the cause of death and/or mentioned in the Coroner's verdict. The deceased had to be aged between 16 and 24 at time of death. This paper includes cases notified up to September 2013.
Analyses were performed using IBM® SPSS® Statistics, version 19 for Windows™.
Demographics, risk factors, and other categorical data were expressed as frequencies and percentages within groups.
RESULTS
Up to September 2013, 30 cases meeting the study criteria had been notified, equating to 43% of notified mephedrone-related fatalities. The first death in this sample occurred in September 2009 and the last in April 2013. Just over half (57%) occurred in England. The age in this group ranged from 17 to just under 25 years; mean age was about 20 years. Most cases were male (73%), lived with others (73%), and where their ethnicity was known (27/30), all were White. Of those with known employment status, 50% were employed. Amongst the 13 whose drug use or addiction status was known, 11 were known drug users (Table 1) .
Where known, only one out of 17 cases had been prescribed drugs (citalopram and diazepam); in 13 cases this status was unknown.
< Table 1 about here > Just under half (47%) died in a defined residential address (typically their own home or that of a friend) and one-quarter (27%) in hospital (Table 2) . Where known (n = 24), the majority had used mephedrone recreationally: eight with a friend, three at a party, two during a night out, and one alone at home. In at least three cases, death followed 'bombing'. Three individuals died in road traffic accidents; for two the drug could have affected their ability to drive. A drowning occurred as a result of impaired judgement following its consumption. Three deaths followed an argument or the ending of a relationship. In two cases suicide followed after changes in mood following consumption, and one as a result of depression. Two-thirds (63%) of cases were considered to be accidental or as the result of misadventure, with abuse of drugs in one case and drug dependence in another. There were three intentional and four possible suicides.
< Table 2 about here > In most cases (63%) accidental poisoning was the underlying cause of death, with 10% accounted for by intentional hanging. Other traumatic deaths involved unintentional hanging, drowning, and firearm and road traffic injuries. Accidental poisoning accounted for half (53%) of proximal (immediate) causes of death. This lower rate is due to more deaths from natural causes (10%). Here too, intentional hanging accounted for 10% of deaths (Table 3 ).
< Table 3 about here > In only 4 cases was mephedrone the sole substance found at post mortem, whilst alcohol and mephedrone only were consumed in a further 4 cases (Table 4 ). Polydrug use with or without alcohol consumption occurred in all remaining cases (n = 22). The most common substances consumed were, in descending frequency: alcohol, benzodiazepines, piperazines, cocaine, opiates/opioids, amphetamine and ecstasy.
< Table 4 about here > Post mortem mephedrone blood levels were available in 17/30 cases (Table 5 ). Where mephedrone was the only substance taken the levels were 0.190 and 3.300mg/L (mean 1.745 mg/L). For cases (n = 6) where only mephedrone was implicated but multiple substances were consumed the mean level was 1.372 (range 0.070-2.240) mg/L. The mean level for cases where mephedrone was implicated with other substances (n = 9) was 0.518 (range 0.002 -2.000>) mg/L. The overall mean was 0.938 (range 0.002-3.300) mg/L. There was one outlier of 22.000 mg/L. Summary details for individual cases are given in Table 6. < Table 5 about here > DISCUSSION This study highlights the dangers for young people aged 16-24 years of consuming mephedrone in association with alcohol, stimulants and/or CNS depressants. Typical victims in this study were male, White, with a history of previous drug use or dependence, and living with others. These demographics are similar to those found in our previous research on mephedrone (Corkery et al., 2012a; Schifano et al., 2012) , as well as for deaths from stimulants more generally.
Death occurred in a private home in just under half (47%) of cases, one quarter (27%) in hospital, and also in a variety of other locations, such as a street, river or park. The majority of cases followed recreational use of mephedrone leading to accidental overdoses/poisonings. Serious concern about the potential toxicity of this drug itself is confirmed by the occurrence of four deaths (13%) where mephedrone was implicated on its own. In a further 8 cases (27%) mephedrone was considered the sole drug implicated although other substances were present post mortem. Mephedrone was found to be implicated with other substances in 18 cases. On average, at least two other substances had been used (Table 5 ). Our findings here reinforce the continuing pattern of polysubstance use by young people. Many of these substances are stimulants (ecstasy, amphetamine, cocaine), piperazines (BZP, TFMPP) and other synthetic cathinones (methylone, MDPV).
According to the literature, other stimulants, such as amphetamine-like drugs, are frequently detected in toxicology reports of mephedrone-associated fatalities, suggesting that simultaneous use of synthetic cathinones with stimulants may amplify, in a synergic way, both dopaminergic and serotoninergic stimulation, and enhance the risk of death (Schifano et al., 2012) . Indeed, one death (case 11) was attributed to Serotonin Toxicity Syndrome (with 4-MA). The co-ingestion of CNS depressants appears to be another common feature of these deaths, specifically alcohol, benzodiazepines (mainly diazepam), and opiates/opioids. This aspect is a well-known risk factor for elevated risk of death .
Where post mortem blood levels were available and excluding an outlier of 22.0 mg/L, the mean mephedrone concentration was 0.938 (range 0.0016-3.300) mg/L. This is in line with our previous findings (Corkery et al., 2012a) and those of Torrance et al. (2010) , some of which cases are included on the NPSAD database. Lower concentrations were found in cases where other substances were implicated and/or consumed compared to cases of solely mephedrone consumption. This suggests that lower dosages of mephedrone can potentially cause/trigger serious adverse consequences when taken in combination with other substances.
The formal conclusions by Coroners and their counterparts reflect the largely recreational circumstances of mephedrone use described here, i.e. accidental/misadventure (63%) and abuse of drugs (7%). We have previously noted growing concern about the addiction potential of synthetic cathinones (Schifano et al., 2012) and other worrying adverse effects on the mental state of individuals consuming mephedrone are worrying (Corkery et al., 2012a) , including in this 16-24 years age-group. Here, we would highlight: (a) impaired judgement leading to fatal road traffic accidents and drowning; and (b) depression, paranoia and psychoses resulting in intentional self-harm leading to death, e.g. hanging (see Table 2 for examples); (c) withdrawal from mephedrone was regarded as a contributory factor in one case.
Study limitations
Blood levels were only available to NPSAD in 17/30 cases; this limits the interpretation of post mortem mephedrone blood concentrations, but can be set beside results from our previous research. Due to the voluntary nature of reporting to NPSAD and the inquest procedures associated with most drug-related deaths, other mephedrone-related deaths may have occurred prior to the publication of this study but which have not yet been reported to the Programme as the inquests into such cases may have not yet been concluded. In most cases, mephedrone was identified in combination with other drugs; hence, it is difficult to describe here the exact role that mephedrone played in the reported fatalities in this agegroup. However, our previous research suggests that mephedrone can be fatally toxic on its own (Corkery et al., 2012a; Schifano et al., 2012) .
CONCLUSIONS
This study describes the largest case-series of mephedrone-related fatalities in young people aged 16-24 years. It confirms that individuals in this age-group are at potential risk of fatal mephedrone toxicity, whether on its own or more likely in combination with other substances, or from adverse mental health issues/depression following its use. Despite being controlled in the UK since April 2010, mephedrone has caused/contributed to fatalities and continues to do so (at least 9 in this age-group in 2011-3); there may be more waiting to be notified. This fact underlines the need for health and other professionals, as well as potential consumers to be alert to the potentially fatal consequences of using mephedrone.
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